Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 6/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.47 |
| ▸ | CHRND | Q07001 | 5/20 | 0.47 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.47 |
| ▸ | CHRNG | P07510 | 1/20 | 0.47 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16509133 | 0.93 | OPRM1 (0.53) | GRIA1OPRM1OPRD1OPRK1CNR1 | |
| SCHEMBL16509049 | 0.93 | PTPN1 (0.49) | GRIA1OPRM1OPRD1OPRK1CNR1 | |
| SCHEMBL16509064 | 0.92 | OPRM1 (0.55) | GRIA1OPRM1OPRD1OPRK1CHRND | |
| SCHEMBL16509070 | 0.91 | PTPN1 (0.51) | GRIA1OPRM1OPRD1OPRK1CNR1 | |
| SCHEMBL16509021 | 0.88 | OPRM1 (0.55) | GRIA1OPRM1OPRD1OPRK1PSMB5 | |
| SCHEMBL16509082 | 0.88 | OPRM1 (0.55) | GRIA1OPRM1OPRD1OPRK1PSMB5 | |
| SCHEMBL16509050 | 0.87 | OPRM1 (0.51) | OPRM1OPRD1OPRK1PSMB5 | |
| SCHEMBL16509109 | 0.86 | OPRD1 (0.53) | GRIA1OPRM1OPRD1OPRK1 | |
| SCHEMBL30685260 | 0.85 | PTPN1 (0.50) | GRIA1OPRM1OPRD1OPRK1CNR1 | |
| SCHEMBL16508987 | 0.84 | OPRD1 (0.52) | GRIA1OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301087-A1 | CRF1 RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301087-A1 | CRF1 RECEPTOR COMPOUNDS | CRHR1, CRH, CRHR2 | GRIA1 126/4885OPRM1 31/4885OPRD1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.